S-ClassAbout S-Class
C
CAPRAI Stock Diagnostic Report
Capricor rises as FDA extends Deramiocel action date
The FDA's extension of the review period for Deramiocel has led to an increase in Capricor's stock price.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$6.800000190734863Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support2.96
Near-Term Resistance8.29
02
FUNDAMENTALS
Financial & Fundamental Analysis
Rather than a direct announcement of financial performance, the regulatory news regarding the extension of the FDA approval review schedule positively impacts the reevaluation of the company's value in the short term.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The current price of $6.80 is positioned between the 20-day resistance level ($8.29) and the support level ($2.96), indicating a phase of pullback or resistance level testing following a short-term surge.
Support2.96
Resistance8.29
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
The FDA has extended the review action date for Deramiocel, strengthening biotech momentum.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-08-24)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.